Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19318311 | METHODS FOR DETECTING INTERCELLULAR INTERACTIONS OF CELLS IN A COMPARTMENT OF A FLUIDIC DEVICE | September 2025 | January 2026 | Allow | 5 | 1 | 0 | Yes | No |
| 19318315 | METHODS FOR INCUBATING AND ANALYZING A CELL IN A COMPARTMENT OF A FLUIDIC DEVICE | September 2025 | January 2026 | Allow | 5 | 1 | 0 | Yes | No |
| 19311988 | SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION | August 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19297604 | Biomarker for Detecting and Treating Type II Diabetes | August 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19294044 | METHODS FOR IMAGING AND ANALYZING A CELL IN A COMPARTMENT OF A FLUIDIC DEVICE | August 2025 | January 2026 | Allow | 6 | 1 | 0 | Yes | No |
| 19278614 | METHODS FOR ENCLOSING AND ANALYZING A CELL IN A FLUIDIC DEVICE | July 2025 | February 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19249710 | SEQUENCING METHODS WITH PARTITIONING | June 2025 | September 2025 | Allow | 3 | 1 | 0 | No | No |
| 19177401 | DEVICES AND METHODS FOR ANALYZING BIOLOGICAL SAMPLES | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19097444 | METHODS AND SYSTEMS FOR PROCESSING POLYNUCLEOTIDES | April 2025 | January 2026 | Allow | 10 | 1 | 0 | Yes | No |
| 19091172 | SYSTEMS AND METHODS FOR SELECTIVE DNA MULTIPLE DISPLACEMENT AMPLIFICATION OF A DNA MIXTURE; | March 2025 | January 2026 | Allow | 10 | 2 | 0 | Yes | No |
| 19088591 | SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION | March 2025 | November 2025 | Allow | 8 | 1 | 0 | No | No |
| 19083328 | METHODS AND SYSTEMS FOR PROCESSING POLYNUCLEOTIDES | March 2025 | October 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 19072459 | METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTS | March 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 19070259 | METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTS | March 2025 | April 2025 | Allow | 2 | 1 | 0 | No | No |
| 19047506 | PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINS | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19029558 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | January 2025 | October 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 19025566 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | January 2025 | October 2025 | Allow | 9 | 1 | 0 | No | No |
| 19014935 | METHOD AND KIT FOR GENOTYPING OF MULTI-SYSTEM RED BLOOD CELL (RBC) BLOOD GROUP BASED ON NEXT-GENERATION SEQUENCING (NGS) | January 2025 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18958854 | SEQUENCING A TARGET SEQUENCE IN A CELL | November 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18936839 | METHODS AND SYSTEMS FOR MONITORING A RECIPIENT OF AN ALLOGRAFT | November 2024 | July 2025 | Allow | 8 | 3 | 0 | Yes | No |
| 18930072 | METHODS FOR MONITORING RESIDUAL DISEASE | October 2024 | February 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18900948 | METHOD, KIT AND SYSTEM FOR END LABELING OF NUCLEIC ACIDS | September 2024 | June 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18813477 | METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTS | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18812385 | METHODS AND SYSTEMS FOR DETECTING GENETIC VARIANTS | August 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18776193 | DEVICES AND METHODS FOR ANALYZING BIOLOGICAL SAMPLES | July 2024 | January 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18770271 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18770298 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | July 2024 | March 2025 | Allow | 8 | 1 | 0 | No | No |
| 18737828 | PROBE-BASED ANALYSIS OF NUCLEIC ACIDS AND PROTEINS | June 2024 | March 2025 | Abandon | 9 | 1 | 0 | No | No |
| 18737230 | SYSTEMS AND METHODS FOR SEQUENCING ERROR CORRECTION VIA DOUBLE STRAND PRESERVATION | June 2024 | September 2024 | Allow | 4 | 1 | 0 | No | No |
| 18677090 | SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION | May 2024 | February 2025 | Allow | 9 | 1 | 0 | No | No |
| 18672154 | Adenosine triphosphatase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 (ATP2A2) gene-based molecular marker for identifying chicken feed efficiency trait, and identification method and use thereof | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18655106 | METHODS FOR PROCESSING NUCLEIC ACID SAMPLES | May 2024 | June 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18625882 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | April 2024 | April 2025 | Allow | 12 | 2 | 0 | No | No |
| 18593787 | METHODS FOR ANALYZING BIOLOGICAL SAMPLES IN A FLUIDIC DEVICE COMPRISING GENERATING A POLYMER MATRIX FROM PRECURSORS AT SPECIFIC LOCATIONS COMPRISING BIOLOGICAL COMPONENTS | March 2024 | July 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18426665 | SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION | January 2024 | January 2025 | Allow | 11 | 1 | 0 | No | No |
| 18392743 | METHODS AND SYSTEMS FOR NUCLEIC ACID ANALYSIS | December 2023 | April 2025 | Abandon | 16 | 2 | 0 | No | No |
| 18569594 | SPATIAL ANALYSIS OF A PLANAR BIOLOGICAL SAMPLE | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18367944 | METHOD FOR THE ANALYSIS OF MINIMAL RESIDUAL DISEASE | September 2023 | July 2025 | Allow | 22 | 1 | 0 | No | No |
| 18243012 | METHODS TO DETECT A SILENT CARRIER GENOTYPE | September 2023 | August 2025 | Allow | 23 | 2 | 0 | No | No |
| 18460755 | SINGLE CELL SEQUENCING | September 2023 | February 2025 | Allow | 17 | 1 | 0 | No | No |
| 18350601 | IMMUNE PROFILING USING SMALL VOLUME BLOOD SAMPLES | July 2023 | July 2025 | Allow | 24 | 1 | 0 | No | No |
| 18347064 | METHODS FOR SPECIES-LEVEL RESOLUTION OF MICROORGANISMS | July 2023 | August 2025 | Allow | 25 | 1 | 0 | No | No |
| 18345676 | METHOD OF DETECTING AND QUANTIFYING GENOMIC AND GENE EXPRESSION ALTERATIONS USING RNA | June 2023 | June 2025 | Allow | 24 | 1 | 0 | No | No |
| 18343858 | MATERIALS AND METHODS FOR LOCALIZED DETECTION OF NUCLEIC ACIDS IN A TISSUE SAMPLE | June 2023 | February 2025 | Allow | 19 | 1 | 0 | No | No |
| 18341446 | METHODS, COMPOSITIONS, AND KITS FOR PREPARING NUCLEIC ACID LIBRARIES | June 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18333730 | SINGLE CELL SEQUENCING LIBRARIES OF GENOMIC TRANSCRIPT REGIONS OF INTEREST IN PROXIMITY TO BARCODES, AND GENOTYPING OF SAID LIBRARIES | June 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18331043 | SIMULTANEOUS QUANTIFICATION OF GENE EXPRESSION IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE | June 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18205795 | DIAGNOSIS OF PROSTATE CANCER | June 2023 | May 2025 | Allow | 24 | 2 | 0 | No | No |
| 18320122 | METHODS AND ARRAYS FOR PRODUCING AND SEQUENCING MONOCLONAL CLUSTERS OF NUCLEIC ACID | May 2023 | January 2025 | Allow | 20 | 1 | 0 | No | No |
| 18313277 | METHODS OF LABELLING NUCLEIC ACIDS USING VARIABLE LENGTH OLIGONUCLEOTIDES | May 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18143268 | DROPLET TAGGING CONTIGUITY PRESERVED TAGMENTED DNA | May 2023 | March 2026 | Allow | 34 | 2 | 0 | No | No |
| 18035073 | METHODS AND SYSTEMS FOR PHASING SEQUENCING STRANDS AND LONG-RANGE SEQUENCING | May 2023 | January 2026 | Allow | 33 | 1 | 0 | No | No |
| 18142512 | MULTIPLEXED METHOD FOR THE IDENTIFICATION AND QUANTITATION OF MINOR ALLELES AND POLYMORPHISMS | May 2023 | July 2025 | Allow | 26 | 2 | 0 | No | No |
| 18303536 | COMPOSITIONS AND METHODS FOR ISOLATION OF CELL-FREE DNA | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18303464 | METHODS, COMPOSITIONS, AND SOLID SUPPORTS FOR MULTI-DIMENSIONAL SEQUENCING | April 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18131675 | DNA SEQUENCING REACTION ADDITIVE | April 2023 | April 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18129747 | CONFORMATIONAL PROBES AND METHODS FOR SEQUENCING NUCLEIC ACIDS | March 2023 | January 2025 | Allow | 22 | 1 | 0 | No | No |
| 18128764 | FRET-BASED ANALYTES DETECTION AND RELATED METHODS AND SYSTEMS | March 2023 | October 2025 | Allow | 31 | 2 | 0 | No | No |
| 18125041 | LOADING NUCLEIC ACIDS ONTO SUBSTRATES | March 2023 | November 2024 | Allow | 20 | 1 | 0 | No | No |
| 18027085 | LINKED DUAL BARCODE INSERTION CONSTRUCTS | March 2023 | January 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18184928 | METHODS AND COMPOSITIONS FOR SEQUENCING DOUBLE STRANDED NUCLEIC ACIDS | March 2023 | June 2025 | Allow | 27 | 2 | 0 | No | No |
| 18043306 | METHODS AND REAGENTS FOR RAPID DETECTION OF PATHOGENS IN BIOLOGICAL SAMPLES | February 2023 | March 2026 | Allow | 37 | 2 | 1 | No | No |
| 18111791 | Colorimetric Detection of Nucleic Acid Amplification | February 2023 | March 2025 | Allow | 25 | 2 | 0 | No | No |
| 18106566 | PURIFICATION OF NUCLEIC ACIDS USING TITANIUM OXIDES | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18164531 | DEVICE FOR EXTRACTING A NUCLEIC ACID FROM A SAMPLE LIQUID | February 2023 | February 2025 | Allow | 25 | 1 | 0 | No | No |
| 18104954 | METHODS AND COMPOSITIONS FOR LOADING OF POLYMERASE COMPLEXES | February 2023 | November 2025 | Abandon | 33 | 1 | 0 | No | No |
| 18017802 | APPARATUS AND METHOD FOR SAMPLING AND DETECTING A PATHOGEN IN AIR | January 2023 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18156739 | KIT FOR GENOTYPING OF PLATELET AND NEUTROPHIL ANTIGENS AND GLYCOPROTEINS | January 2023 | January 2026 | Allow | 36 | 1 | 0 | Yes | No |
| 18154008 | Water-Soluble Prolamin, Preparation Thereof, and Uses Thereof for Food-Grade Application Including Prolamin Compositions Combining Prolamin and DNA Taggants | January 2023 | January 2026 | Allow | 36 | 2 | 1 | No | No |
| 18053603 | ERROR CORRECTION IN AMPLIFICATION OF SAMPLES | November 2022 | March 2025 | Allow | 28 | 3 | 0 | No | No |
| 17976030 | CHEMICAL DENATURATION FOR OLIGONUCLEOTIDE ANALYSIS | October 2022 | January 2026 | Allow | 39 | 1 | 0 | No | No |
| 18050382 | SEQUENCE TAG DIRECTED SUBASSEMBLY OF SHORT SEQUENCING READS INTO LONG SEQUENCING READS | October 2022 | July 2024 | Allow | 21 | 1 | 0 | No | No |
| 18046058 | PRIMER EXTENSION TARGET ENRIGHMENT AND IMPROVEMENTS THERETO INCLUDING SIMULTANEOUS ENRICHMENT OF DNA AND RNA | October 2022 | January 2025 | Allow | 27 | 1 | 1 | No | No |
| 17934407 | METHODS OF SEQUENCING CIRCULAR TEMPLATE POLYNUCLEOTIDES | September 2022 | September 2024 | Allow | 24 | 3 | 0 | No | No |
| 17820011 | METHOD OF NUCLEIC ACID ENRICHMENT USING SITE-SPECIFIC NUCLEASES FOLLOWED BY CAPTURE | August 2022 | August 2024 | Allow | 24 | 1 | 1 | No | No |
| 17886769 | TCR/BCR Profiling Using Enrichment with Pools of Capture Probes | August 2022 | May 2024 | Allow | 22 | 1 | 0 | No | No |
| 17819397 | SYSTEMS AND METHODS FOR PROCESSING-NUCLEIC ACID MOLECULES FROM A SINGLE CELL USING SEQUENTIAL CO-PARTITIONING AND COMPOSITE BARCODES | August 2022 | July 2024 | Allow | 23 | 1 | 0 | No | No |
| 17816662 | Sequencing Output Determination and Analysis with Target-Associated Molecules in Quantification Associated with Biological Targets | August 2022 | August 2024 | Allow | 25 | 2 | 0 | No | No |
| 17816272 | NUCLEIC ACID REARRANGEMENT AND INTEGRATION ANALYSIS | July 2022 | October 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17831641 | SEPARATION OF NUCLEIC ACID COMPONENT COMPOUNDS ON ZWITTERIONIC STATIONARY PHASES | June 2022 | December 2025 | Allow | 42 | 1 | 0 | No | No |
| 17830897 | POLYMERASE CHAIN REACTION NORMALIZATION THROUGH PRIMER TITRATION | June 2022 | March 2026 | Allow | 45 | 3 | 0 | No | No |
| 17828686 | DNA CONSTRUCT FOR SEQUENCING AND METHOD FOR PREPARING THE SAME | May 2022 | March 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17825315 | METHODS FOR DETECTING THE PRESENCE OR ABSENCE OF A CHROMOSOME REARRANGEMENT IN A FORMALIN-FIXED PARAFFIN EMBEDDED (FFPE) SAMPLE WITH NO DETECTABLE GENOMIC VARIANT ASSOCIATED WITH CANCER | May 2022 | October 2025 | Allow | 41 | 1 | 0 | No | No |
| 17779351 | METHOD AND SYSTEM FOR DETECTION OF EXTRAINTESTINAL E. COLI STRAINS PATHOGENIC TO POULTRY | May 2022 | March 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17749050 | SYSTEMS AND METHODS FOR DIFFERENTIALLY TAGGING NUCLEIC ACID MOLECULES | May 2022 | July 2024 | Allow | 26 | 1 | 0 | No | No |
| 17755083 | Thermally Responsive Conjugates For DNA Polymerase Inhibition | April 2022 | August 2025 | Allow | 40 | 1 | 0 | No | No |
| 17723494 | METHOD FOR CONSTRUCTING SECOND-GENERATION SEQUENCING LIBRARY OF RNA AND DNA, AND SECOND-GENERATION SEQUENCING KIT | April 2022 | January 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17718412 | ENHANCED IMMUNE CELL RECEPTOR SEQUENCING METHODS | April 2022 | October 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17632710 | Method and Apparatus for Single-Cell Analysis for Determining a Cell Trajectory | February 2022 | September 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17502526 | METHODS AND COMPOSITIONS FOR CAPPING NUCLEIC ACIDS | October 2021 | September 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17497090 | Methods for Categorizing and Treating Subjects Having Cystic Fibrosis (CF) and at Risk for Severe Pulmonary Exacerbation | October 2021 | July 2024 | Allow | 33 | 3 | 0 | No | No |
| 17602643 | COMPOSITION FOR DIAGNOSIS OR PROGNOSIS PREDICTION OF GLIOMA, AND METHOD FOR PROVIDING INFORMATION RELATED THERETO | October 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17492318 | Systems and Methods for Rapid Nucleic Acid Extraction, Purification and Analysis from Semen | October 2021 | April 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17600526 | IMMOBILIZATION IN FLOW CELLS | September 2021 | April 2025 | Allow | 42 | 0 | 1 | No | No |
| 17448736 | DETERMINING THE SEQUENCE OF A DOUBLE-STRANDED TARGET NUCLEIC ACID BY EMPLOYING A TERMINAL TRANSFERASE, FORMING A LINEAR JOINT MOLECULE, AND SEQUENCING IN ONE DIRECTION | September 2021 | November 2024 | Allow | 38 | 1 | 0 | No | No |
| 17483274 | AFFINITY-OLIGONUCLEOTIDE CONJUGATES AND USES THEREOF | September 2021 | October 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17447794 | METHODS FOR PREPARING A SAMPLE FOR NUCLEIC ACID AMPLIFICATION USING TAGMENTATION | September 2021 | August 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17436513 | HIGH ACCURACY NANOPORE-BASED SINGLE MOLECULE SEQUENCING BY SYNTHESIS WITH TAGGED NUCLEOTIDES | September 2021 | July 2025 | Allow | 46 | 1 | 0 | No | No |
| 17399339 | METHOD FOR QUANTIFICATION OF PD-L1 EXPRESSION | August 2021 | January 2025 | Allow | 42 | 3 | 0 | Yes | No |
| 17392531 | ISOTHERMAL METHODS FOR AMPLIFYING NUCLEIC ACID SAMPLES | August 2021 | May 2025 | Allow | 46 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HORLICK, KENNETH R.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 34.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner HORLICK, KENNETH R works in Art Unit 1681 and has examined 315 patent applications in our dataset. With an allowance rate of 96.8%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner HORLICK, KENNETH R's allowance rate of 96.8% places them in the 87% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by HORLICK, KENNETH R receive 1.80 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HORLICK, KENNETH R is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a -0.1% benefit to allowance rate for applications examined by HORLICK, KENNETH R. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 34.3% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 63.8% of cases where such amendments are filed. This entry rate is in the 88% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 92.6% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 84.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 54.2% are granted (fully or in part). This grant rate is in the 55% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 26.7% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.7% of allowed cases (in the 57% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.